In connection with the Stock Purchase Agreement, RPI and OMERS provided their written consent of the consummation of the sale of the Company’s European ORLADEYO business.
the Company entered into a license agreement granting an Irish affiliate of Neopharmed Gentili S.p.A. exclusive rights to commercialize navenibart for hereditary angioedema in Europe
The Company receives quarterly royalty payments from BioCryst Ireland equal to amounts owed under its Royalty Purchase Agreements with RPI and OMERS for the sale of ORLADEYO products in the Territory.
Product revenue where the specialty pharmacy is considered the customer was approximately 93 % and 85 % of total product sales for the three months ended March 31, 2026 and 2025, respectively.
BioCryst Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BCRX-DEBT
Debt stack $858.1M
90%
Market cache reports total debt of $858.1M.
BCRX-DEBT-8104
Warrants outstanding: 11765000
90%
xbrl warrant detail from xbrl 2020-12-31.
BioCryst Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioCryst Pharmaceuticals, Inc..
BioCryst Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
BCRX-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 302 tracked holders.
BioCryst Pharmaceuticals, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
